Plain-English translation of NCT05954312 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This is a first-in-human study testing a new drug called designed to help fight advanced cancers. The study will test whether this medication is safe and whether it works better when given alone or combined with chemotherapy drugs or immunotherapy that doctors already use. Researchers are trying to find the right dose and understand how the medication works in the body.
Many people with advanced solid tumors run out of treatment options when their cancer stops responding to standard therapies. This medication works on a new target in cancer cells, and this trial aims to see if it could offer hope to patients who have limited choices.
You likely qualify if…
You likely don't qualify if…
Participants will take the medication by mouth once or twice daily in cycles lasting 21 to 28 days, depending on which treatment arm they are assigned to. Some participants will receive the medication alone, while others will receive it combined with standard chemotherapy drugs given intravenously every few weeks. You would need regular visits for blood tests, imaging scans to measure your tumors, and check-ups to monitor how you are responding and managing any side effects. The study is designed to find the safest and most effective dose before expanding to more participants.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
United States